FY2024 EPS Estimates for ICON Public Increased by Analyst

ICON Public Limited (NASDAQ:ICLR) – Research analysts at William Blair raised their FY2024 EPS estimates for shares of ICON Public in a research note issued to investors on Wednesday, January 15th. William Blair analyst M. Smock now anticipates that the medical research company will post earnings per share of $13.55 for the year, up from their prior estimate of $13.40. William Blair has a “Outperform” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.41 per share. William Blair also issued estimates for ICON Public’s FY2025 earnings at $13.33 EPS.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 earnings per share.

ICLR has been the topic of several other reports. Redburn Atlantic started coverage on shares of ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target on the stock. The Goldman Sachs Group decreased their target price on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research note on Wednesday, January 15th. Truist Financial restated a “buy” rating and set a $284.00 target price (down previously from $295.00) on shares of ICON Public in a research note on Wednesday, December 18th. Finally, Leerink Partners reissued an “outperform” rating and set a $255.00 price target (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ICON Public presently has a consensus rating of “Moderate Buy” and an average target price of $287.00.

ICON Public Trading Down 2.2 %

Shares of NASDAQ:ICLR opened at $198.11 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The stock has a market capitalization of $16.34 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 1.59 and a beta of 1.20. The stock’s 50-day simple moving average is $209.71 and its two-hundred day simple moving average is $267.52. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72.

Institutional Investors Weigh In On ICON Public

Large investors have recently modified their holdings of the business. Avior Wealth Management LLC grew its position in shares of ICON Public by 76.0% in the 4th quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company’s stock worth $187,000 after buying an additional 386 shares during the last quarter. Park Place Capital Corp increased its stake in shares of ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares during the period. Steph & Co. lifted its position in ICON Public by 3.7% during the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after purchasing an additional 55 shares during the period. GAMMA Investing LLC raised its stake in shares of ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after buying an additional 169 shares during the last quarter. Finally, Foyston Gordon & Payne Inc acquired a new position in ICON Public in the third quarter valued at approximately $11,672,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.